US 2016/0257664 A1 · NOVEL COMPOUNDS

Abstract

The present invention is directed to crystalline forms of a compound which has retinoid-related orphan receptor gamma (RORγ) modulator activity, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.

Claims17

Dependent claims

A crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

Dependencies are inferred from the claim text.

Facts

Application

15/031,323Filed 23 Oct 2014

Priority

25 Oct 2013

Published

8 Sep 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

C07D 309/06
With only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms: radicals substituted by oxygen…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/18
Drugs for disorders of the alimentary tract or the digestive system: for pancreatic disorders, e.g. pancreatic enzymes
A61P 3/00
Drugs for disorders of the metabolism

Abstract

Claims17

Dependent claims

A crystalline form of N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

Dependencies are inferred from the claim text.

Novel compounds

Life of this patent

Abstract

Claims17

Novel compounds

Life of this patent

Abstract

Claims17